NanoViricides, Inc. (NYSE American: NNVC) announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage of the clinical-stage antiviral drug developer with an “Outperform” rating and a $6.00 price target. The report reviews the company’s lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.
Separately, the company announced that President and Executive Chairman Anil R. Diwan participated in a “Fireside Chat” published by StockInvestor Daily’s IPO-Edge program, where he discussed NanoViricides’ antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company’s regulatory progress, including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox and Ebola.
The initiation of coverage by Noble Capital Markets is significant for NanoViricides as it provides independent validation of the company’s technology and pipeline. The $6 price target suggests substantial upside from current trading levels, reflecting confidence in NV-387 and other programs. NV-387 is a broad-spectrum antiviral drug candidate that the company plans to develop for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, as well as mpox/smallpox and measles. The drug has received FDA Orphan Drug Designation for certain indications, which could accelerate development and provide market exclusivity.
NanoViricides’ platform technology is based on nanomedicine, using specially designed nanomaterials to target viruses. The company holds exclusive licenses from TheraCour Pharma for several antiviral drugs. Beyond NV-387, NanoViricides has other candidates in development, including NV-HHV-1 for shingles and formulations for COVID-19 that encapsulate remdesivir. The company’s broad pipeline addresses a range of viral diseases, including herpes, influenza, HIV, hepatitis, rabies, dengue, and Ebola.
The analyst report and executive commentary underscore the growing interest in NanoViricides as infectious diseases resurge globally. With the FDA’s Rare Pediatric Disease Designation filing for measles, the company is positioning itself to address unmet medical needs in pediatric populations. The company’s focus on broad-spectrum antivirals is particularly relevant given the emergence of new viral variants and the need for treatments that work across multiple pathogens.
For more information, see the full press release at https://ibn.fm/7XBbY and the company’s newsroom at https://ibn.fm/NNVC.
